Assuming all options for BCMA-directed therapy are available, how would you approach treatment for a patient with 4 prior lines of myeloma-directed therapy who is eligible for a BCMA-directed therapy?  

Great question with no right answer. I note, for example, that the original question stem asks about overall therapy approaches while the subsequent poll asks about effectiveness. With regard to effectiveness in isolation, I think it's fair to say that cilta-cel (a CAR-T therapy) has the best track ...